Home ABEO
3.99
  Price2.84%   +0.11
(After Hours: 3.99 +0.00 +0.00%)
loading

Abeona Therapeutics (ABEO) Latest News

Nov-29-22 03:44AM Philips (PHG) Showcases New AI-Based Solutions at the RSNAZacks Investment Research
Nov-14-22 07:30AM Abeona Therapeutics Reports Third Quarter 2022 Financial ResultsGlobeNewswire Inc.
Nov-08-22 02:28AM Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'Benzinga
02:21AM 5 Penny Stocks To Buy According To Analysts, Targets Up To 995%PennyStocks
Nov-03-22 07:31AM Abeona Therapeutics Announces $35 Million Private Placement FinancingGlobeNewswire Inc.
Oct-19-22 07:30AM Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) GlobeNewswire Inc.
Oct-17-22 05:21AM Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From FridayBenzinga
Oct-10-22 02:16AM Best Penny Stocks To Buy? 3 To Watch During The Stock Market CrashPennyStocks
05:28AM Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From FridayBenzinga
Oct-07-22 02:06AM Best Penny Stocks To Buy Now? 4 Biotech Stocks To WatchPennyStocks
12:27PM Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday's Mid-Day SessionBenzinga
Oct-04-22 07:30AM Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)GlobeNewswire Inc.
Sep-22-22 07:30AM Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine SummitGlobeNewswire Inc.
Sep-19-22 11:18AM Philips (PHG) to Showcase New Innovations & Cardiac SolutionsZacks Investment Research
Sep-13-22 07:30AM Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines ConferenceGlobeNewswire Inc.
Sep-09-22 03:11AM Philips (PHG) Expands Partnership to Build Angio CT SolutionZacks Investment Research
Sep-07-22 02:22AM Philips (PHG) Alerts Users of Health Hazards of Therapy MasksZacks Investment Research
Aug-11-22 07:30AM Abeona Therapeutics Reports Second Quarter 2022 Financial ResultsGlobeNewswire Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. Abeona Therapeutics Inc. also has a license agreement with REGENXBIO Inc. to NAV AAV9 vector for the treatment of Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten, and Juvenile Batten diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
Cap:    |  Volume (24h):